Activin and Inhibin

BMS-770767 is an 11β-hydroxysteroid dehydrogenase 1 ( 11β-HSD1 ) inhibitor in type 2 diabetes. 11β-HSD1 is an important enzyme that is widely expressed in liver, adipose tissue and other tissues and plays an important role in metabolic diseases such

BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC 50 of 3.0 nMIn Vitro11β-HSD1 inhibition may be useful in the treatment of type II diabetes and other

BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC 50 of 3.0 nMIn Vitro11β-HSD1 inhibition may be useful in the treatment of type II diabetes and other

BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC 50 of 3.0 nMIn Vitro11β-HSD1 inhibition may be useful in the treatment of type II diabetes and other

BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC 50 of 3.0 nMIn Vitro11β-HSD1 inhibition may be useful in the treatment of type II diabetes and other

BMS-816336 is a novel, potent and orally bioavailable inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with an IC 50 of 3.0 nMIn Vitro11β-HSD1 inhibition may be useful in the treatment of type II diabetes and other

BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor. BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial

BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor. BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial

BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor. BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial

BMS-963272 is a potent, selective MGAT2 inhibitor ( IC 50 = 7.1 nM) for the research of metabolic disorders.Form:Solid.

BMS-963272 is a potent, selective MGAT2 inhibitor ( IC 50 = 7.1 nM) for the research of metabolic disorders.Form:Solid.

BMS-963272 is a potent, selective MGAT2 inhibitor ( IC 50 = 7.1 nM) for the research of metabolic disorders.Form:Solid.